Applied Genetic Technologies Corporation AGTC
At closeNov 30, 2022, 4:00 PM EST
52-week range unavailable
- Revenue (ttm)
- 325.00K
- Shares out
- 67.63M
- Forward P/E
- -0.27
- Volume
- 764.53K
- Open
- 0.37
- Previous close
- 0.3936
- Day's range
- 0.37 – 0.40
- Beta
- 1.58
- Analysts
- Hold
- Price target
- 0.34 (-13.6%)
- Earnings date
- Dec 6, 2022
2Y -2.3564 (-85.69%)
Key statistics
- Enterprise value
- 12.20M
- PEG ratio
- 0.00
- Price / sales
- 81.91
- Price / book
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -40.30M
- Total cash
- 34.24M
- Total debt
- 20.15M
- Return on equity
- -161.14%
- Short % of float
- 2.05%
- 50-day average
- 0.34974
- 200-day average
- 0.665742
Analyst view
Consensus: hold
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Dec 6, 2022
Expected Dec 6, 2022. Consensus EPS estimate -0.36.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 6, 2022 | Sep 1, 2022 | -0.28 | — | — | — |
| Oct 6, 2022 | Jun 1, 2022 | -0.30 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -0.42 | — | — | — |
| Feb 14, 2022 | Dec 1, 2021 | -0.38 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.35 | — | — | — |
| Sep 23, 2021 | Jun 1, 2021 | -0.37 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 25, 2022 | Wells Fargo | main | — | Equal-Weight |
| Oct 25, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 24, 2022 | Wedbush | down | Outperform | Neutral |
| Oct 24, 2022 | Stifel | down | Buy | Hold |
| Oct 4, 2022 | Wells Fargo | down | Overweight | Equal-Weight |
| Sep 30, 2022 | Stifel | main | — | Buy |
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- agtc.com
News
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022 
Make Money With Penny Stocks in November? 3 Methods to Use 
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday - Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket 
Stocks That Hit 52-Week Lows On Tuesday 
Stocks That Hit 52-Week Lows On Thursday - Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
- Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Wednesday
Your note
Sign in to keep a note on AGTC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALISKI WILLIAM E | Director | Purchase | Dec 13, 2018 | 8,500 |
| FEINSOD MATTHEW | Officer | Stock Award(Grant) | Jul 10, 2019 | 56,052 |
| KOENIG SCOTT | Director | Conversion of Exercise of derivative security | May 27, 2019 | 34,246 |
| KROL PATRICK JOHAN HENDRIK | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 25, 2019 | 0 |
| POTTER STEPHEN W | Officer | Sale | Jun 30, 2022 | 55,883 |
| REYNOLDS GERALD ANTHONY | Officer | Stock Award(Grant) | Aug 18, 2022 | 51,006 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Portolan Capital Management, LLC | 2.37% | 1,600,902 | 630.12K | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 2.18% | 1,477,636 | 581.60K | Sep 29, 2022 |
| Millennium Management Llc | 2.15% | 1,455,882 | 573.03K | Sep 29, 2022 |
| Interwest Venture Management Co. | 2.08% | 1,404,515 | 552.82K | Sep 29, 2022 |
| Kingdon Capital Management LLC | 1.81% | 1,225,000 | 482.16K | Sep 29, 2022 |
| Renaissance Technologies, LLC | 1.68% | 1,137,508 | 447.72K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.98% | 1,340,980 | 527.81K | Jun 29, 2022 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 1.80% | 1,216,061 | 478.64K | Aug 30, 2022 |
| Vanguard Extended Market Index Fund | 0.82% | 556,629 | 219.09K | Jun 29, 2022 |
| Fidelity NASDAQ Composite Index ETF | 0.41% | 280,625 | 110.45K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.38% | 257,117 | 101.20K | Aug 30, 2022 |
| iShares Micro Cap ETF | 0.17% | 115,229 | 45.35K | Sep 29, 2022 |